Company intelligence / Profile preview
OverT Bio
New York, New York, United Statesovert.bio ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
OverT Bio is developing cell therapies for solid tumors using innovative screening platforms to identify genes that can enhance T cell efficacy against cancer. No clinical results reported yet as they appear to be in pre-clinical development.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyEngineered immune cellsGenetically enhanced allogeneic gamma delta T cells
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Strategic collaboration with Nona Biosciences (announced October 9, 2024)
Beyond the preview
Go deeper on OverT Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OverT Bio.